Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Respiratory Safety of Vornorexant in Mild OSA
NCT04746105Phase 1Completed
- Sponsor
- Taisho Pharmaceutical
- Start
- Feb 2021
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Insomnia comparing TS-142 with Placebo (2 arms). Primary endpoint: Apnea Hypopnea Index at Day 1. Started Feb 2021; status: completed.
02
Drugs
vornorexant
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT04746105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04746105.